Search alternatives:
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
38141
A Conductive Bamboo Fabric with Controllable Resistance for Tailoring Wearable Sensors
Published 2022“…The volume resistivity (ρ<sub>v</sub>) decreases with increasing weft and linear densities, too. …”
-
38142
Calorie restriction leads to telomere maintenance and/or elongation with time in a percentage of mice.
Published 2013“…<p>(A, C and E) The behavior of mean telomere length was classified in two different profiles (“Decrease” and “Increase or Maintenance”) at different times of diet (1–22 months of diet, 5–22 months of diet and 9–22 months of diet; A, C and E, respectively) in the indicated groups. …”
-
38143
-
38144
-
38145
-
38146
Treatment of 2D cell culture by a γ-secretase inhibitor.
Published 2016“…B. Aβ42 levels were significantly decreased in all 5 AD subjects after treatment with the γ-secretase inhibitor at all doses tested. …”
-
38147
A large proportion of NSCs redivide within 24 to 72 h.
Published 2020“…(B–E) Example DLS (yellow arrow) for a labeling interval Δt = 9 h. (F) The DLS proportion is high for Δt = 9 h and decreases rapidly with increasing Δt. …”
-
38148
-
38149
Baseline characteristics.
Published 2024“…The montelukast group exhibited a decreased incidence rate of transaminase elevations (0.7% vs 1.4% per day, HR: 0.48, 95%CI 0.25–0.90, P = 0.023).…”
-
38150
Subgroup analyses for the primary outcome.
Published 2024“…The montelukast group exhibited a decreased incidence rate of transaminase elevations (0.7% vs 1.4% per day, HR: 0.48, 95%CI 0.25–0.90, P = 0.023).…”
-
38151
Outcomes.
Published 2024“…The montelukast group exhibited a decreased incidence rate of transaminase elevations (0.7% vs 1.4% per day, HR: 0.48, 95%CI 0.25–0.90, P = 0.023).…”
-
38152
Trial profile.
Published 2024“…The montelukast group exhibited a decreased incidence rate of transaminase elevations (0.7% vs 1.4% per day, HR: 0.48, 95%CI 0.25–0.90, P = 0.023).…”
-
38153
Utilizing reduction in spheroid counts and/or total nuclear intensity to determine toxic effects of compounds.
Published 2023“…They are indicated appropriately in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0287809#pone.0287809.g004" target="_blank">Fig 4</a>. …”
-
38154
-
38155
Synthesis of a Dialuminum-Substituted Silicotungstate and the Diastereoselective Cyclization of Citronellal Derivatives
Published 2008“…The reaction of <b>1</b> with pyridine yielded TBA<sub>3</sub>[(C<sub>5</sub>H<sub>5</sub>N)H][γ-SiW<sub>10</sub>O<sub>36</sub>{Al(C<sub>5</sub>H<sub>5</sub>N)}<sub>2</sub>(μ-OH)<sub>2</sub>]·2H<sub>2</sub>O (<b>2</b>), and the molecular structure was successfully determined by the X-ray crystallographic analysis. …”
-
38156
Synthesis of a Dialuminum-Substituted Silicotungstate and the Diastereoselective Cyclization of Citronellal Derivatives
Published 2008“…The reaction of <b>1</b> with pyridine yielded TBA<sub>3</sub>[(C<sub>5</sub>H<sub>5</sub>N)H][γ-SiW<sub>10</sub>O<sub>36</sub>{Al(C<sub>5</sub>H<sub>5</sub>N)}<sub>2</sub>(μ-OH)<sub>2</sub>]·2H<sub>2</sub>O (<b>2</b>), and the molecular structure was successfully determined by the X-ray crystallographic analysis. …”
-
38157
GGA3 deletion induces a reduction in anxiety-like behaviors.
Published 2016“…<p>GGA3 null mice display decreased anxiety-like behaviors in two different testing paradigms (A-C: Elevated Plus Maze; D-F: Light-Dark Transition). …”
-
38158
Comorbidity and progression of late onset Alzheimer’s disease: A systematic review
Published 2017“…<div><p>Background</p><p>Alzheimer’s disease is a neurodegenerative syndrome characterized by multiple dimensions including cognitive decline, decreased daily functioning and psychiatric symptoms. …”
-
38159
-
38160
Supplement information is provided in a separate file named “S1 File”.
Published 2015“…<p><b>Table A—BC−/EC+ exhibited decreased ejection fraction and increased end-systolic and end-diastolic volumes (Table A is included in the “S1 File”).…”